
Cyclacel Pharmaceuticals CYCC
Annual report 2025
added 03-30-2026
Cyclacel Pharmaceuticals P/S Ratio 2011-2026 | CYCC
Annual P/S Ratio Cyclacel Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 0.13 | 18.4 | - | - | 5.9 K | - | 63.7 | - | 19.3 | 6.03 | 7.34 | 50.8 | 595 | 41 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.9 K | 0.13 | 670 |
P/S Ratio of other stocks in the Biotechnology industry
| Issuer | P/S Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.75 | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
94.1 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.53 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
1.96 K | - | 2.54 % | $ 160 B | ||
|
Autolus Therapeutics plc
AUTL
|
4.27 | $ 1.34 | -3.6 % | $ 357 M | ||
|
Midatech Pharma plc
MTP
|
137 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.39 K | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
0.142 | - | -24.86 % | $ 820 K | ||
|
DBV Technologies S.A.
DBVT
|
500 | $ 20.13 | -1.13 % | $ 2.81 B | ||
|
Alterity Therapeutics Limited
ATHE
|
131 | $ 3.65 | 1.3 % | $ 8.78 B | ||
|
Advaxis
ADXS
|
144 | - | -9.65 % | $ 45.9 M | ||
|
Dyadic International
DYAI
|
10.2 | $ 0.87 | - | $ 31.5 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 | - | - | $ 86.2 M | ||
|
Aytu BioScience
AYTU
|
0.237 | $ 2.57 | -3.57 % | $ 16.1 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.61 | - | - | - | ||
|
Equillium
EQ
|
1.77 | $ 2.04 | 1.24 % | $ 117 M | ||
|
Aeterna Zentaris
AEZS
|
7.87 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
0.099 | - | -10.17 % | $ 12.2 K | ||
|
Fate Therapeutics
FATE
|
28.1 | $ 1.13 | -5.04 % | $ 134 M | ||
|
Aeglea BioTherapeutics
AGLE
|
489 | - | - | $ 1.01 B | ||
|
Forte Biosciences
FBRX
|
181 | $ 26.57 | 0.49 % | $ 344 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
65.5 | - | - | $ 26.5 M | ||
|
Fennec Pharmaceuticals
FENC
|
3.78 | $ 6.14 | -4.36 % | $ 175 M | ||
|
Foghorn Therapeutics
FHTX
|
11.5 | $ 4.74 | -2.87 % | $ 299 M | ||
|
AIkido Pharma
AIKI
|
0.935 | - | 1.93 % | $ 17.4 M | ||
|
Amicus Therapeutics
FOLD
|
6.98 | $ 14.46 | 0.03 % | $ 4.46 B | ||
|
Fulcrum Therapeutics
FULC
|
0.00291 | $ 7.55 | -3.58 % | $ 478 K | ||
|
CureVac N.V.
CVAC
|
281 | - | - | $ 867 M | ||
|
BioNTech SE
BNTX
|
35.7 | $ 87.65 | -3.98 % | $ 27.2 B | ||
|
Gilead Sciences
GILD
|
6.23 | $ 138.19 | -1.38 % | $ 172 B | ||
|
Coherus BioSciences
CHRS
|
5.36 | $ 1.61 | -3.59 % | $ 189 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
73.3 | $ 0.54 | 4.26 % | $ 503 K | ||
|
Genmab A/S
GMAB
|
15.6 | $ 27.01 | -2.67 % | $ 17.2 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
11 | $ 314.44 | -4.81 % | $ 41.2 B | ||
|
Gossamer Bio
GOSS
|
2.22 | $ 0.32 | -7.11 % | $ 73.1 M | ||
|
Grifols, S.A.
GRFS
|
1.71 | $ 7.91 | -3.95 % | $ 6.83 B | ||
|
Alpine Immune Sciences
ALPN
|
8.94 | - | - | $ 2.17 B | ||
|
Halozyme Therapeutics
HALO
|
6.91 | $ 63.51 | 0.68 % | $ 7.61 B | ||
|
Burford Capital Limited
BUR
|
6.35 | $ 4.42 | -1.34 % | $ 727 M |